Chiron is asking for as much as 30% of Herceptin sales until its patent expires in 2005. That could total more than $300 million. The trial, which began Aug. 6 in Sacramento, is expected to go to ...

Herceptin’s main US patent expires this month, paving the way for cut-price competition in the US at last. Herceptin’s US sales were just over $2.9 billion last year, ...

Swiss pharmaceutical giant Roche says it is abandoning a patent for top-selling breast cancer drug Herceptin in the Indian market, paving the way for local drugmakers to make a cheaper generic ...

Herceptin has been on the market since 1998.The many patents on it are set to expire this year.On June 13, the FDA hit a milestone by approving its 20th biosimilar — drugs that are akin to ...

India's Biocon received approval for a generic version of Roche's breast-cancer drug Herceptin in India. Roche had decided not to seek patent approval for the drug there.

Roche had filed for a patent on Herceptin on 11 October 2000, and this had been granted on 6 April 2007, but faced a post-grant challenge. Photo: AFP (AFP ) ...

Roche was awarded an Indian patent on Herceptin in 2007 that extends to 2019, and the additional patents do not extend the time before biosimilar versions could be launched. The depth of Roche’s IP ...

Chiron Corp. filed another patent infringement lawsuit against rival biotechnology company Genentech Inc. related to Genentech's breast cancer drug Herceptin, according to a federal filing.

Herceptin’s main US patent expires this month, paving the way for cut-price competition in the US at last. Herceptin’s US sales were just over $2.9 billion last year, ...